ATE538809T1 - Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff - Google Patents

Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Info

Publication number
ATE538809T1
ATE538809T1 AT04746847T AT04746847T ATE538809T1 AT E538809 T1 ATE538809 T1 AT E538809T1 AT 04746847 T AT04746847 T AT 04746847T AT 04746847 T AT04746847 T AT 04746847T AT E538809 T1 ATE538809 T1 AT E538809T1
Authority
AT
Austria
Prior art keywords
vaccine
selecting appropriate
biological sample
precursor cells
highly responsive
Prior art date
Application number
AT04746847T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE538809T1 publication Critical patent/ATE538809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT04746847T 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff ATE538809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (ja) 2003-06-27 2004-06-25 Ｗｔ１ワクチン適応患者の選択方法

Publications (1)

Publication Number Publication Date
ATE538809T1 true ATE538809T1 (de) 2012-01-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04746847T ATE538809T1 (de) 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Country Status (9)

Country Link
US (1) US10500257B2 (de)
EP (3) EP2338509B1 (de)
JP (1) JP4566912B2 (de)
KR (2) KR101292971B1 (de)
CN (1) CN1842603B (de)
AT (1) ATE538809T1 (de)
CA (2) CA2530184C (de)
ES (3) ES2443582T3 (de)
WO (1) WO2005001117A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
EP1371664B1 (de) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
CA2530184C (en) 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
TW200817680A (en) * 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
US10093977B2 (en) * 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP5478260B2 (ja) * 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
EP2561759A1 (de) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum
EP2755484A1 (de) 2011-09-16 2014-07-23 Bayer Intellectual Property GmbH Verwendung von 5-phenyl- oder 5-benzyl-2-isoxazolin-3-carboxylaten für erhöhten pflanzenertrag
CN103929956B (zh) 2011-09-16 2017-02-22 拜耳知识产权有限责任公司 酰基磺酰胺用于改善植物产量的用途
MX362112B (es) 2011-09-16 2019-01-07 Bayer Ip Gmbh Uso de fenilpirazolin-3-carboxilatos para mejorar el rendimiento de las plantas.
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US9226955B2 (en) 2012-10-23 2016-01-05 Ubivac, Llc Allogeneic autophagosome-enriched composition for the treatment of disease
EA201591168A1 (ru) 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
CN110078813B (zh) * 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
ES2734235T3 (es) 2013-03-05 2019-12-04 Bayer Cropscience Ag Uso de combinaciones que comprenden cloquintocet-mexilo para la mejora del rendimiento en plantas
BR112015021449B1 (pt) 2013-03-05 2020-05-05 Bayer Cropscience Ag uso de acilsulfonamidas para melhorar a produção da planta
BR112015024780A2 (pt) * 2013-03-28 2017-10-10 Ct Hospitalier Universitaire Montpellier metodo para determinar radiosensibilidade
CA2912514A1 (en) * 2013-05-13 2014-11-20 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
EP3318135A1 (de) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Sprudelndes süssigkeitenmaterial, verfahren zu dessen herstellung und daraus hergestellte produkte
BR112020011469A2 (pt) 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
MX2022014249A (es) * 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
JP7835418B1 (ja) * 2025-01-14 2026-03-25 国立大学法人神戸大学 がんワクチンの効果予測

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JPH07504399A (ja) 1991-08-28 1995-05-18 ザ・ウィスター・インスティチュート Ｔ細胞リセプターに基づいた慢性間接リウマチの治療法
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
KR100262838B1 (ko) * 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1159457B1 (de) 1999-02-23 2010-11-03 Baylor College Of Medicine T-ZELLREZEPTOR Vb-Db-Jb-SEQUENZ UND VERFAHREN FÜR IHREN NACHWEIS
CA2410510A1 (en) * 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
EP1371664B1 (de) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
EP1473564A4 (de) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd Verfahren zum nachweis von zellimmunität und dessen anwendung auf arzneistoffe
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
CN1688708A (zh) 2002-01-09 2005-10-26 曼盛基因技术有限公司 检测t细胞增殖的基因序列方法
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
CA2530184C (en) 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
WO2005053603A2 (en) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Antigen receptor variable region typing
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자

Also Published As

Publication number Publication date
EP2338509A3 (de) 2011-11-30
JPWO2005001117A1 (ja) 2006-08-10
HK1090093A1 (en) 2006-12-15
EP2343083A3 (de) 2011-08-03
KR20110049877A (ko) 2011-05-12
JP4566912B2 (ja) 2010-10-20
ES2378156T3 (es) 2012-04-09
WO2005001117A1 (ja) 2005-01-06
EP2338509B1 (de) 2014-06-18
EP1640458A4 (de) 2008-05-21
EP2343083B1 (de) 2014-01-15
ES2478446T3 (es) 2014-07-22
KR101292971B1 (ko) 2013-08-12
ES2443582T3 (es) 2014-02-19
KR101431312B1 (ko) 2014-08-20
CA2893995A1 (en) 2005-01-06
CA2530184A1 (en) 2005-01-06
CA2530184C (en) 2015-10-06
KR20060069363A (ko) 2006-06-21
US20070128207A1 (en) 2007-06-07
EP1640458B1 (de) 2011-12-28
EP2343083A2 (de) 2011-07-13
EP2338509A2 (de) 2011-06-29
EP1640458A1 (de) 2006-03-29
CN1842603A (zh) 2006-10-04
CN1842603B (zh) 2013-09-11
US10500257B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
EP1640458A4 (de) Verfahren zur auswahl von für den wt1-impfstoff geeigneten patienten
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60039310D1 (de) Verfahren zur bestimmung von amyloidogenen proteinen
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
DE602005020956D1 (de) Verfahren und gerät zur identifikation von lebendigen eiern mittels pulsfrequenz und embryobewegung
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
Lu et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
ATE184703T1 (de) Verfahren und testsatz zur messung von endogenen zytokinen
EA201170365A1 (ru) Способ и устройство диагностики и скрининга заболеваний с использованием электромагнитных полей сверхнизкой частоты
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
JP5866053B1 (ja) 皮膚粘弾性のマーカー及びその利用
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
DE60025170D1 (de) Diagnostisches verfahren für asthma
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
DE10391021D2 (de) Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens